statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Incyte (Nasdaq:INCY) announced today that it has scheduled its first quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, April 30, 2024. The schedule for the press...

Incyte to Report First Quarter Financial Results

Trust Point Inc. bought a new stake in Incyte Co. (NASDAQ:INCY - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange...

Trust Point Inc. Buys Shares of 11,332 Incyte Co. (NASDAQ:INCY)

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Incyte gets payment from CMS Skinhealth for povorcitinib commercialization

Incyte, CMS enter collaboration, license agreement for povorcitinib in China

Incyte (Nasdaq:INCY) (Incyte) and China Medical System Holdings Limited (CMS or the Group) are pleased to announce that on March 31, 2024, Incyte and CMS, through a wholly-owned dermatology medical...

Incyte and CMS Announce Collaboration and License Agreement for Povorcitinib, an Oral JAK1 Inhibitor, in Mainland China, Hong Kong, Macau, Taiwan and Southeast Asia

Povorcitinib, a selective oral JAK1 inhibitor discovered by Incyte, is an investigational medicine being evaluated for the treatment of non-segmental vitiligo, hidradenitis suppurativa (HS), prurigo...

CMS and Incyte Announce Collaboration and License Agreement for Povorcitinib in China and Southeast Asia

In this piece, we will take a look at the 12 best S&P 500 stocks to buy according to analysts. If you want to skip our coverage of the latest happenings surrounding one of America's most widely...

12 Best S&P 500 Stocks To Buy According to Analysts

Incyte (Nasdaq:INCY) announced today that it granted equity inducement awards to Matteo Trotta, the Companys new Executive Vice President and General Manager of U.S. Dermatology, pursuant to the...

Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Royal Bank of Canada restated their sector perform rating on shares of Incyte (NASDAQ:INCY  Free Report) in a research note published on Monday morning, Benzinga reports. They currently have...

Incyte (NASDAQ:INCY) Given "Sector Perform" Rating at Royal Bank of Canada

Incyte participates in a conference call with JPMorgan

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. The company was founded in April 1991 and is headquartered in Wilmington, DE.

Volume	2.49M
52-Wk High	$75.74
52-Wk Low	$50.27

INCY Incyte Corp.

About

Feed

News

Sentiment

Earnings

Fundamentals